Use of serum biomarkers in a diagnostic test for irritable bowel syndrome

Cytokines;Chemokines;生物标志物;细胞因子;趋化因子;MSD;Cytokines;Chemokines
浏览次数:29 分享:

Lembo, A., J, Neri, B., Tolley, J., Barken, D., Carroll, S., Pan, H.

  • Aliment Pharmacol Ther.
  • 2009
  • 9.524
  • 16(2):389-97.
  • Human,Mouse,Non-Human Primate,Rat
  • MSD
  • Serum
  • 消化系统
  • 肠炎
  • BDNF, TIMP-1, TWEAK

相关货号

LXMH05-1LXMH10-9LXMH22-1LXMH87-1LXMM05-1LXMM08-1LXMM13-1LXMM58-1LXMR02-4LXMR05-1LXMR12-1

Abstract

Amyloid-beta(Abeta) aggregation is a major hallmark of Alzheimer's disease (AD). Previous studies have suggested that only unbound Abeta can take part in the aggregation process. Therefore, endogenous Abeta-binding proteins may have an important role in preventing AD. Here, we analyzed cerebrospinal fluid (CSF) samples from 35 subjects with AD, 18 subjects with frontotemporal dementia (FTD) and 29 non-demented controls to test if reduced Abeta-binding capacity in CSF is a specific feature of AD. A panel of known Abeta-binding CSF proteins, including beta-trace/prostaglandin D2 synthase (beta-trace), transthyretin (TTR), cystatin C (CysC) and alpha(1)-antitrypsin (AAT), were quantified and related to diagnosis and CSF levels of Abeta(1-38), Abeta(1-40) and Abeta(1-42). AD patients displayed a mild reduction in the CSF levels of beta-trace (p=0.020), CysC (p=0.017), AAT (p=0.019) and TTR (p=0.012) compared with controls. While the reductions in AAT and TTR were AD-specific, the levels of beta-trace and CysC were also reduced in FTD. As expected, CSF Abeta(1-42) was reduced in AD compared with controls (p=0.00005) and with FTD patients (p=0.015). Positive correlations between Abeta(1-42) and beta-trace, CysC and TTR, respectively, were seen only in the AD group, suggesting that deficient Abeta-binding capacity in CSF may contribute to the amyloidogenic process in AD.
金课堂之文献解析 文献原文请点击

技术文章 更多

    研究领域 更多

      热点文献